We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AMD is the second strongest semiconductor maker behind Nvidia (NVDA), the market leader. However, the race for AI supremacy is sending demand to unfathomable levels, and NVDA will not be able to keep up fully for the foreseeable future. AMD has emerged as a strong challenger to Nvidia’s graphic processing unit or GPU market dominance. Zacks Consensus Estimates suggest that by 2024, AMD will report record annual results, and in turn, AMD stock should follow with all-time highs.
Image Source: Zacks Investment Research
Catch Up Candidate
Though it often makes sense to be invested in the industry leader, AMD is becoming more attractive from a valuation perspective and could play catch up. AMD has a P/E ratio of just 43x, much more reasonable than NVDA’s 92.47x.
Image Source: Zacks Investment Research
Chart Pattern
AMD shares have exhibited relative strength recently and are looking to emerge from a bullish wedge pattern.
Novavax is a biotech company that develops innovative vaccines to prevent serious infectious diseases. The company came to prominence when it was in the race with companies such as Johnson and Johnson ((JNJ - Free Report) ), Pfizer ((PFE - Free Report) ), and Moderna ((MRNA - Free Report) ) to get a COVID-19 vaccine approved. Unfortunately for NVAX, it took until July 13th, 2022 to receive emergency use authorization from the US FDA. However, recent reports show that COVID-19 numbers are on the rise again.
Reversion to the Mean Potential
If COVID-19 numbers continue to pick up and the NVAX vaccine goes mainstream, the reversion to the mean potential is signficant. Earnings are expected to reach record levels by the end of 2023. Meanwhile, the stock is well off its high (above $250, now at ~$10).
Image Source: Zacks Investment Research
Recipe for a Short Squeeze
At 48% short interest, Novavax is among the most heavily shorted stocks in the market. As of Wednesday, shares are back above the critical 200-day moving average for the first time since late 2021. A close above the 200-day moving average will likely cause more shorts to panic and cover – sending shares much higher.
Image Source: TradingView
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Stocks on the Mend: A Mean Reversion Duo
September is starting in classic, historically weak form. However, in an earlier piece, I provided readers with three reasons why September may actually offer a bullish surprise for investors. Even with the somewhat weak start, investors must not get overly bearish without proof. For now, the Nasdaq 100 ETF ((QQQ - Free Report) ) is simply retesting its 50-day moving average and breakout zone from above.
Image Source: TradingView
Below are two stocks with comeback potential, strong fundamental stories, and explosive technical setups:
Advanced Micro Devices ((AMD - Free Report) )
AMD is the second strongest semiconductor maker behind Nvidia (NVDA), the market leader. However, the race for AI supremacy is sending demand to unfathomable levels, and NVDA will not be able to keep up fully for the foreseeable future. AMD has emerged as a strong challenger to Nvidia’s graphic processing unit or GPU market dominance. Zacks Consensus Estimates suggest that by 2024, AMD will report record annual results, and in turn, AMD stock should follow with all-time highs.
Image Source: Zacks Investment Research
Catch Up Candidate
Though it often makes sense to be invested in the industry leader, AMD is becoming more attractive from a valuation perspective and could play catch up. AMD has a P/E ratio of just 43x, much more reasonable than NVDA’s 92.47x.
Image Source: Zacks Investment Research
Chart Pattern
AMD shares have exhibited relative strength recently and are looking to emerge from a bullish wedge pattern.
Image Source: TradingView
Novavax ((NVAX - Free Report) )
Novavax is a biotech company that develops innovative vaccines to prevent serious infectious diseases. The company came to prominence when it was in the race with companies such as Johnson and Johnson ((JNJ - Free Report) ), Pfizer ((PFE - Free Report) ), and Moderna ((MRNA - Free Report) ) to get a COVID-19 vaccine approved. Unfortunately for NVAX, it took until July 13th, 2022 to receive emergency use authorization from the US FDA. However, recent reports show that COVID-19 numbers are on the rise again.
Reversion to the Mean Potential
If COVID-19 numbers continue to pick up and the NVAX vaccine goes mainstream, the reversion to the mean potential is signficant. Earnings are expected to reach record levels by the end of 2023. Meanwhile, the stock is well off its high (above $250, now at ~$10).
Image Source: Zacks Investment Research
Recipe for a Short Squeeze
At 48% short interest, Novavax is among the most heavily shorted stocks in the market. As of Wednesday, shares are back above the critical 200-day moving average for the first time since late 2021. A close above the 200-day moving average will likely cause more shorts to panic and cover – sending shares much higher.
Image Source: TradingView